Former NCI, NIH directors voice concern over cancer trial funding cuts

Former directors of the National Cancer Institute and National Institutes of Health, Kimryn Rathmell, MD, PhD, and Monica Bertagnolli, MD, respectively, who both served during the Biden administration, have shared their concerns over the Trump administration’s efforts to limit funding indirect costs for scientific research. 

Advertisement

A federal judge ordered a temporary, nationwide restraining order Feb. 10, blocking a new policy that would have capped funding of indirect costs for research institutions at 15%.

In a Feb. 11 NPR report, Dr. Rathmell said the funding cuts could immediately impact cancer research. 

“Some of those trials aren’t going to open,” she told NPR. “There are some patients out there who are going to get that news.” 

Dr. Bertagnolli expressed her disapproval of funding cuts in a Feb. 10 post on LinkedIn

“Damaging the robustness of medical research in the US by forcing universities to curtail research projects that will now run in the red in order to save $4 [billion] at NIH is a terrible idea,” she said. “This will result in nationwide losses in present value of manyfold more billions in order to save four.”

Advertisement

Next Up in Oncology

Advertisement

Comments are closed.